Klotho Neurosciences
Yahoo Finance • 13 days ago
Klotho Neurosciences to acquire select assets from Turn Biotechnologies
* Klotho Neurosciences (NASDAQ:KLTO [https://seekingalpha.com/symbol/KLTO]) said on Tuesday that it has signed a Letter of Intent (LOI) [https://seekingalpha.com/pr/20248846-klotho-neurosciences-signs-letter-of-intent-to-acquire-select-a... Full story
Yahoo Finance • 2 months ago
Klotho Neurosciences advances ALS treatment candidate toward clinical trials
NEW YORK - Klotho Neurosciences, Inc. (NASDAQ:KLTO), a biotechnology company with a current market capitalization of $45.33 million, has received Orphan Drug Designation from the FDA for its KLTO-202 candidate for the treatment of Amyotrop... Full story
- T
Mentioned:
Yahoo Finance • 3 months ago
Klotho Neurosciences regains full compliance with Nasdaq listing standards
* Klotho Neurosciences (NASDAQ:KLTO [https://seekingalpha.com/symbol/KLTO]) received [https://seekingalpha.com/pr/20167393-klotho-neurosciences-inc-regains-full-compliance-with-nasdaq-minimum-closing-bid-price-and]a notification letter f... Full story
Yahoo Finance • 3 months ago
Klotho Neurosciences regains NASDAQ compliance
NEW YORK - Klotho Neurosciences, Inc. (NASDAQ:KLTO), a gene and cell therapy company with a market capitalization of $71.15 million, has regained compliance with NASDAQ’s continued listing requirements, the company announced Wednesday. Acc... Full story
Yahoo Finance • 3 months ago
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerat... Full story
Yahoo Finance • 3 months ago
Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS
Investing.com -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its novel secreted-Klotho promoter, gene and del... Full story
Yahoo Finance • 3 months ago
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational... Full story
Yahoo Finance • 4 months ago
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene
NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, including ALS, Alzheimer’s Disease (AD) and Par... Full story
Yahoo Finance • 4 months ago
Klotho Neurosciences terminates share exchange agreement with SkyBell
NEW YORK - Klotho Neurosciences, Inc. (NASDAQ:KLTO), a $50.37 million market cap biotech company whose shares have surged 243% over the past six months, announced on Wednesday that it has formally ended its Share Exchange Agreement with Sk... Full story
Yahoo Finance • 4 months ago
Catalyst Watch: Middle East tension, Paris Air Show, FOMC meeting, and triple-witching day
[A double exposure image of skyscrapers with overlay of financial graphs, set against a blurred background, illustrating the concept of business growth] peshkov Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week'... Full story
